An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer
This is a phase 1 study to test different doses of a new investigational drug called
CFI-400945 to see which dose is safer in people. This study will also look at the safety of
CFI-400945 and to study its effects on patients with advanced cancers. This drug has been
tested in animals but not yet in people.
CFI-400945 is an oral (taken by mouth) drug that works by blocking polo-like kinase 4 (PLK4)
from working. PLK4 is a protein that is important in regulating cell growth and division and
cell death. Many tumours are shown to make too much PLK4. When there is too much PLK4
produced, it is believed to lead to uncontrolled cancer cell growth and division. Therefore,
by blocking this protein from working, it is believed to stop tumours growing or shrink them.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society